Scientific Advisory Board

Jonathan Fletcher, M.D. is a lab-based medical and pediatric oncologist at Harvard Medical School, Brigham and Women’s Hospital, and Dana-Farber Cancer Institute in Boston, Massachusetts. His research goals have been to identify and characterize oncogenic mutations in sarcoma. By identifying and studying such mutations, his lab has pinpointed biologic mechanisms regulating sarcoma and GIST cell growth and survival. Dr. Fletcher’s other lab commitments include creation of biologically representative sarcoma cell lines, discovery and validation of novel targeted therapies, and correlative science studies to demonstrate mechanisms of response and resistance to targeted therapies. Dr. Fletcher also coordinates an international research consortium devoted to maximizing therapeutic response in GIST.

John M. McCall, Ph.D. has 37 years of experience in the pharmaceutical industry. Most recently he left Pfizer to form PharMac in early 2005. At Pfizer, he served as a vice president in the research organization. He subsequently held the position of global head of chemistry with Pharmacia & Upjohn, and Pharmacia. Prior to this, he was head of Upjohn's CNS unit. John currently serves on steering committees for NINDS, works as an advisor to several foundations, serves on multiple SABs and consults.

Judith S. Sebolt‑Leopold, Ph.D. is a Research Associate Professor in the Center for Molecular Imaging at the University of Michigan Medical School. She has 23 years of pharmaceutical industry experience and has led multiple research teams, resulting in the advancement of four oncology clinical candidates including the first clinically tested MEK inhibitor. Before leaving Pfizer in 2007, she served as Executive Director of the Mechanistic & Target Biology department. Judy received her undergraduate degree from Wellesley College and a Ph.D. in Biological Sciences from Purdue University. She then carried out postdoctoral studies in Experimental Oncology at Indiana University School of Medicine. She has a publication record that includes over eighty invited reviews, peer reviewed articles, and issued patents.

Richard A. Van Etten, M.D., Ph.D. is internationally recognized for his groundbreaking research focusing on chronic myeloid leukemia and other hematological malignancies. He directs a research laboratory, funded by the National Institutes of Health and the Leukemia & Lymphoma Society, at the Tufts Medical Center's Molecular Oncology Research Institute (MORI) in Boston, Massachusetts. Rick is currently serving as the Director of Tufts Medical Center's Cancer Center and as Chief of the Division of Hematology/Oncology, a position that he has held since 2006. He is an Associate Editor of the journal, “Blood”, a member of the Leukemia Committee of the Eastern Cooperative Oncology Group and past chair of the Myeloid Neoplasia Committee of the American Society of Hematology. Rick received his M.D. and Ph.D. from Stanford University School of Medicine.